PHARMING GROUP NV - ADR (PHAR) Stock Price, Quote, News and Overview
NASDAQ:PHAR - Nasdaq - US71716E1055 - ADR - Currency: USD
PHAR Quote, Performance and Key Statistics
NASDAQ:PHAR (2/21/2025, 8:00:01 PM)
8.86
-0.09 (-1.01%)
The current stock price of PHAR is 8.86 USD. In the past month the price decreased by -4.63%. In the past year, price decreased by -24.6%.
PHAR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PHAR
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 415 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV - ADR
Darwinweg 24
Leiden ZUID-HOLLAND 2333 CR NL
CEO: Sijmen de Vries
Employees: 382
Company Website: https://www.pharming.com/
Investor Relations: https://www.pharming.com/investors/upcoming-events
Phone: 31715247400
PHARMING GROUP NV - ADR / PHAR FAQ
What is the stock price of PHARMING GROUP NV - ADR today?
The current stock price of PHAR is 8.86 USD. The price decreased by -1.01% in the last trading session.
What is the ticker symbol for PHARMING GROUP NV - ADR stock?
The exchange symbol of PHARMING GROUP NV - ADR is PHAR and it is listed on the Nasdaq exchange.
On which exchange is PHAR stock listed?
PHAR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PHARMING GROUP NV - ADR stock?
12 analysts have analysed PHAR and the average price target is 15.73 USD. This implies a price increase of 77.54% is expected in the next year compared to the current price of 8.86. Check the PHARMING GROUP NV - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PHARMING GROUP NV - ADR worth?
PHARMING GROUP NV - ADR (PHAR) has a market capitalization of 601.02M USD. This makes PHAR a Small Cap stock.
How many employees does PHARMING GROUP NV - ADR have?
PHARMING GROUP NV - ADR (PHAR) currently has 382 employees.
What are the support and resistance levels for PHARMING GROUP NV - ADR (PHAR) stock?
PHARMING GROUP NV - ADR (PHAR) has a support level at 8.81 and a resistance level at 9.21. Check the full technical report for a detailed analysis of PHAR support and resistance levels.
Is PHARMING GROUP NV - ADR (PHAR) expected to grow?
The Revenue of PHARMING GROUP NV - ADR (PHAR) is expected to grow by 18.78% in the next year. Check the estimates tab for more information on the PHAR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PHARMING GROUP NV - ADR (PHAR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PHAR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PHAR, evaluating the profitability, health, valuation and growth aspects
- PHARMING GROUP NV - ADR (PHAR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHARMING GROUP NV - ADR (PHAR) Sales and EPS estimates to see what analysts future expectations are.
- PHARMING GROUP NV - ADR (PHAR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHARMING GROUP NV - ADR (PHAR) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHARMING GROUP NV - ADR (PHAR) Stock Chart to make your own analysis
- PHARMING GROUP NV - ADR (PHAR) Latest news and press-releases to stay up to date.
Does PHARMING GROUP NV - ADR (PHAR) stock pay dividends?
PHAR does not pay a dividend.
When does PHARMING GROUP NV - ADR (PHAR) report earnings?
PHARMING GROUP NV - ADR (PHAR) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of PHARMING GROUP NV - ADR (PHAR)?
PHARMING GROUP NV - ADR (PHAR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the Short Interest ratio of PHARMING GROUP NV - ADR (PHAR) stock?
The outstanding short interest for PHARMING GROUP NV - ADR (PHAR) is 0.01% of its float. Check the ownership tab for more information on the PHAR short interest.
PHAR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PHAR. When comparing the yearly performance of all stocks, PHAR is a bad performer in the overall market: 68.23% of all stocks are doing better.
PHAR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHAR. PHAR has only an average score on both its financial health and profitability.
PHAR Financial Highlights
Over the last trailing twelve months PHAR reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -3.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.19% | ||
| ROE | -7.89% | ||
| Debt/Equity | 0.53 |
PHAR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to PHAR. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 0.22% and a revenue growth 18.78% for PHAR